Amid Covishield row, what WHO says on side-effects from Covid vaccine? Should you be worried?
Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement.
Serum Institute of India looks beyond COVID with new vaccines for malaria, dengue
Serum Institute joins CEPI network for vaccines against unknown pathogens (Disease X)
The Serum Institute of India (SII), world's largest vaccine maker by volumes on Wednesday said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation (WHO), making the vaccine eligible to be procured by United Nations agencies and Gavi, the Vaccine Alliance. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/serum-institutes-multivalent-meningococcal-meningitis-vaccine-gets-who-prequalification/articleshow/101703126.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Serum HPV vaccine Cervavac hits mkt; 2-3 mn doses this yr
After teaming up in a partnership last year, the Serum Institute of Life Sciences is doubling its stake in biosimilar manufacturer Biocon Biologics to $300 million.
Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults
India is preparing to include human papillomavirus (HPV) vaccines as part of the government driven public immunization program popularly known as the “Universal Immunization Program (UIP)”. The Indian government will float a global tender in April 2023 to procure HPV vaccines. Against this backdrop, domestic player the Serum Institute of India (SII) is expected to be the front runner to win this tender due to its anticipated affordable pricing, says GlobalData, a leading data and analytics company.